Search
Xencor Inc
XNCRAdd to Watchlist
20.210USD
-1.280-5.96%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.50BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Xencor Inc is 8.29, ranking 143 out of 385 in the Biotechnology & Medical Research industry. The average price target is 27.00, with a high of 42.00 and a low of 17.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
29.636
Target Price
+51.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Xencor Inc
XNCR
14
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Xencor Inc's expected revenue for the next quarter?
Xencor Inc's expected revenue is 18.92M.
What is Xencor Inc's price target?
Analysts forecast that Xencor Inc's price target is USD 27.00, with the highest forecast at USD 42.00 and the lowest forecast at USD 17.00.
How have Xencor IncXNCR's recent earnings per share performed?
The market expectation was USD -1.71, while Xencor IncXNCR's earnings per share (EPS) for the previous quarter was USD -0.09. EPS for the next quarter is expected at USD -0.83.
What is the analyst rating for Xencor Inc?
Based on the ratings of Xencor Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.